SINGLE-PHOTON EMISSION COMPUTERIZED TOMOGRAPHY WITH 99mTC-1-THIO-D-GLUCOSE IN THE STAGING OF LYMPHOMAS
Authors:   Cancer Research Institute, Tomsk National Research Medical Center, Tomsk, Russia, Chernov V.I. ,   Research Centrum for Oncotheranostics, Research School of Chemistry and Applied Biomedical Sciences, Tomsk Polytechnic University, Tomsk, Russia, Dudnikova E.A. ,   Cancer Research Institute, Tomsk National Research Medical Center, Tomsk, Russia, Goldberg V.E. ,   Cancer Research Institute, Tomsk National Research Medical Center, Tomsk, Russia, Goldberg A.V. ,   Cancer Research Institute, Tomsk National Research Medical Center, Tomsk, Russia, Kravchuk T.L. ,   Cancer Research Institute, Tomsk National Research Medical Center, Tomsk, Russia, Muravleva A.V. ,   Cancer Research Institute, Tomsk National Research Medical Center, Tomsk, Russia, Zelchan R.V. ,   Cancer Research Institute, Tomsk National Research Medical Center, Tomsk, Russia,   Research Centrum for Oncotheranostics, Research School of Chemistry and Applied Biomedical Sciences, Tomsk Polytechnic University, Tomsk, Russia, Medvedeva A.A. ,   Cancer Research Institute, Tomsk National Research Medical Center, Tomsk, Russia, Bragina O.D. ,   Cancer Research Institute, Tomsk National Research Medical Center, Tomsk, Russia,   Research Centrum for Oncotheranostics, Research School of Chemistry and Applied Biomedical Sciences, Tomsk Polytechnic University, Tomsk, Russia, Rybina A.N. ,   Cancer Research Institute, Tomsk National Research Medical Center, Tomsk, Russia
Published: October 2022

Purpose: To study the possibility of using SPECT with a new radiopharmaceutical 99mTc-1-thio-D-glucose (99mTc-TG) for staging lymphomas. Material and methods: The study included 53 patients with a verified diagnosis of lymphoma (38 people – the main group) and adenopathy of non-tumor origin (15 patients - the comparison group). All patients of the main group underwent 99mTc-TG SPECT, CT of the chest, abdominal organs and all interested areas, ultrasound, and biopsy followed by histological and immunohistochemical studies. Five patients underwent additional 18F-FDG PET/CT. The reference verification methods were histological and IHC examination or, if it was impossible to perform it, clinical observation of the patient for a year with standard control instrumental studies, 18F-FDG PET/CT and 99mTc-TG SPECT. In the comparison group, 99mTc-TG SPECT was performed once before the biopsy. Results: It was shown that 99mTc-TG SPECT made it possible to identify hypermetabolic foci in 75 % of the affected lymph nodes and in 81 % of extranodal formations established by reference diagnostic methods. The low sensitivity 99mTc-TG SPECT are due to the low diagnostic efficiency of the method in detecting lesions in the abdominal cavity and are associated with a high background blood activity and a physiological increase in the accumulation of 99mTc-TG in the kidneys and bladder. However, the method allowed additional visualization of nodal and extranodal lesions in 7 and 9 % of cases, respectively. However, the method allowed additional visualization of nodal and extranodal lesions in 7 % and 9 % of cases, respectively. A study of persons in the comparison group showed that 99mTc-TG SPECT has a high specificity (93 %) in the diagnosis of lymphomas. Conclusion: The 99mTc-TG SPECT with has a high specificity (93 %) in the diagnosis of lymphomas and can be used as an additional method of investigation in the staging of lymphoproliferative diseases.